STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Pharma (STO:MOB)
POSITIVE PHASE 2 DATA FOR BUPI AND GROWTH FINANCING SECURED
FIRST QUARTER
Revenue MSEK 69.5 (73.2)
Moberg Pharma (STO:MOB)
POSITIVE PHASE 2 DATA FOR BUPI AND GROWTH FINANCING SECURED
FIRST QUARTER
Revenue MSEK 69.5 (73.2)